Since either MMPs or SGLT2 have important roles in cardiac-fibrosis under hyperglycemia, we aimed to examine the role of SGLT2 inhibitor dapagliflozin (DAP) on cardiac Zn<sup>2+</sup>-transporters responsible for [Zn<sup>2+</sup>]<sub>i</sub>-regulation, comparison to insulin (INS), together with MMP levels and systemic oxidative stress status in MetS-rats.